Decitabine reactivated pathways in platinum resistant ovarian cancer

Fang Fang, Qingyao Zuo, Jay Pilrose, Yinu Wang, Changyu Shen, Meng Li, Phillip Wulfridge, Daniela Matei, Kenneth Nephew

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Combination therapy with decitabine, a DNMTi and carboplatin resensitized chemoresistant ovarian cancer (OC) to platinum inducing promising clinical activity. We investigated gene-expression profiles in tumor biopsies to identify decitabine-reactivated pathways associated with clinical response. Gene-expression profiling was performed using RNA from paired tumor biopsies before and 8 days after decitabine from 17 patients with platinum resistant OC. Bioinformatic analysis included unsupervised hierarchical-clustering, pathway and GSEA distinguishing profiles of "responders" (progression-free survival, PFS > 6 months) and "non-responders" (PFS < 6 months). Functional validation of selected results was performed in OC cells/tumors. Pre-treatment tumors from responders expressed genes associated with enhanced glycosphingolipid biosynthesis, translational misregulation, decreased ABC transporter expression, TGF-β signaling, and numerous metabolic pathways. Analysis of post-treatment biopsies from responders revealed overexpression of genes associated with reduced Hedgehog pathway signaling, reduced DNA repair/replication, and cancer-associated metabolism. GO and GSEA analyses revealed upregulation of genes associated with glycosaminoglycan binding, cell-matrix adhesion, and cell-substrate adhesion. Computational findings were substantiated by experimental validation of expression of key genes involved in two critical pathways affected by decitabine (TGF-β and Hh). Gene-expression profiling identified specific pathways altered by decitabine and associated with platinum-resensitization and clinical benefit in OC. Our data could influence patient stratification for future studies using epigenetic therapies.

Original languageEnglish
Pages (from-to)3579-3589
Number of pages11
JournalOncotarget
Volume5
Issue number11
StatePublished - 2014

Fingerprint

decitabine
Platinum
Ovarian Neoplasms
Gene Expression Profiling
Neoplasms
Biopsy
Cell-Matrix Junctions
Genes
Glycosphingolipids
Critical Pathways
ATP-Binding Cassette Transporters
Carboplatin
Therapeutics
Metabolic Networks and Pathways
Glycosaminoglycans
Computational Biology
DNA Replication
Transcriptome
Epigenomics
Cell Adhesion

Keywords

  • Chemosensitization
  • Decitabine
  • DNA methylation
  • Gene expression
  • Pathway analysis
  • Platinum resistant ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Fang, F., Zuo, Q., Pilrose, J., Wang, Y., Shen, C., Li, M., ... Nephew, K. (2014). Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget, 5(11), 3579-3589.

Decitabine reactivated pathways in platinum resistant ovarian cancer. / Fang, Fang; Zuo, Qingyao; Pilrose, Jay; Wang, Yinu; Shen, Changyu; Li, Meng; Wulfridge, Phillip; Matei, Daniela; Nephew, Kenneth.

In: Oncotarget, Vol. 5, No. 11, 2014, p. 3579-3589.

Research output: Contribution to journalArticle

Fang, F, Zuo, Q, Pilrose, J, Wang, Y, Shen, C, Li, M, Wulfridge, P, Matei, D & Nephew, K 2014, 'Decitabine reactivated pathways in platinum resistant ovarian cancer', Oncotarget, vol. 5, no. 11, pp. 3579-3589.
Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M et al. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget. 2014;5(11):3579-3589.
Fang, Fang ; Zuo, Qingyao ; Pilrose, Jay ; Wang, Yinu ; Shen, Changyu ; Li, Meng ; Wulfridge, Phillip ; Matei, Daniela ; Nephew, Kenneth. / Decitabine reactivated pathways in platinum resistant ovarian cancer. In: Oncotarget. 2014 ; Vol. 5, No. 11. pp. 3579-3589.
@article{ab9c2d2d2e764b59829ccf8f82152eee,
title = "Decitabine reactivated pathways in platinum resistant ovarian cancer",
abstract = "Combination therapy with decitabine, a DNMTi and carboplatin resensitized chemoresistant ovarian cancer (OC) to platinum inducing promising clinical activity. We investigated gene-expression profiles in tumor biopsies to identify decitabine-reactivated pathways associated with clinical response. Gene-expression profiling was performed using RNA from paired tumor biopsies before and 8 days after decitabine from 17 patients with platinum resistant OC. Bioinformatic analysis included unsupervised hierarchical-clustering, pathway and GSEA distinguishing profiles of {"}responders{"} (progression-free survival, PFS > 6 months) and {"}non-responders{"} (PFS < 6 months). Functional validation of selected results was performed in OC cells/tumors. Pre-treatment tumors from responders expressed genes associated with enhanced glycosphingolipid biosynthesis, translational misregulation, decreased ABC transporter expression, TGF-β signaling, and numerous metabolic pathways. Analysis of post-treatment biopsies from responders revealed overexpression of genes associated with reduced Hedgehog pathway signaling, reduced DNA repair/replication, and cancer-associated metabolism. GO and GSEA analyses revealed upregulation of genes associated with glycosaminoglycan binding, cell-matrix adhesion, and cell-substrate adhesion. Computational findings were substantiated by experimental validation of expression of key genes involved in two critical pathways affected by decitabine (TGF-β and Hh). Gene-expression profiling identified specific pathways altered by decitabine and associated with platinum-resensitization and clinical benefit in OC. Our data could influence patient stratification for future studies using epigenetic therapies.",
keywords = "Chemosensitization, Decitabine, DNA methylation, Gene expression, Pathway analysis, Platinum resistant ovarian cancer",
author = "Fang Fang and Qingyao Zuo and Jay Pilrose and Yinu Wang and Changyu Shen and Meng Li and Phillip Wulfridge and Daniela Matei and Kenneth Nephew",
year = "2014",
language = "English",
volume = "5",
pages = "3579--3589",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - Decitabine reactivated pathways in platinum resistant ovarian cancer

AU - Fang, Fang

AU - Zuo, Qingyao

AU - Pilrose, Jay

AU - Wang, Yinu

AU - Shen, Changyu

AU - Li, Meng

AU - Wulfridge, Phillip

AU - Matei, Daniela

AU - Nephew, Kenneth

PY - 2014

Y1 - 2014

N2 - Combination therapy with decitabine, a DNMTi and carboplatin resensitized chemoresistant ovarian cancer (OC) to platinum inducing promising clinical activity. We investigated gene-expression profiles in tumor biopsies to identify decitabine-reactivated pathways associated with clinical response. Gene-expression profiling was performed using RNA from paired tumor biopsies before and 8 days after decitabine from 17 patients with platinum resistant OC. Bioinformatic analysis included unsupervised hierarchical-clustering, pathway and GSEA distinguishing profiles of "responders" (progression-free survival, PFS > 6 months) and "non-responders" (PFS < 6 months). Functional validation of selected results was performed in OC cells/tumors. Pre-treatment tumors from responders expressed genes associated with enhanced glycosphingolipid biosynthesis, translational misregulation, decreased ABC transporter expression, TGF-β signaling, and numerous metabolic pathways. Analysis of post-treatment biopsies from responders revealed overexpression of genes associated with reduced Hedgehog pathway signaling, reduced DNA repair/replication, and cancer-associated metabolism. GO and GSEA analyses revealed upregulation of genes associated with glycosaminoglycan binding, cell-matrix adhesion, and cell-substrate adhesion. Computational findings were substantiated by experimental validation of expression of key genes involved in two critical pathways affected by decitabine (TGF-β and Hh). Gene-expression profiling identified specific pathways altered by decitabine and associated with platinum-resensitization and clinical benefit in OC. Our data could influence patient stratification for future studies using epigenetic therapies.

AB - Combination therapy with decitabine, a DNMTi and carboplatin resensitized chemoresistant ovarian cancer (OC) to platinum inducing promising clinical activity. We investigated gene-expression profiles in tumor biopsies to identify decitabine-reactivated pathways associated with clinical response. Gene-expression profiling was performed using RNA from paired tumor biopsies before and 8 days after decitabine from 17 patients with platinum resistant OC. Bioinformatic analysis included unsupervised hierarchical-clustering, pathway and GSEA distinguishing profiles of "responders" (progression-free survival, PFS > 6 months) and "non-responders" (PFS < 6 months). Functional validation of selected results was performed in OC cells/tumors. Pre-treatment tumors from responders expressed genes associated with enhanced glycosphingolipid biosynthesis, translational misregulation, decreased ABC transporter expression, TGF-β signaling, and numerous metabolic pathways. Analysis of post-treatment biopsies from responders revealed overexpression of genes associated with reduced Hedgehog pathway signaling, reduced DNA repair/replication, and cancer-associated metabolism. GO and GSEA analyses revealed upregulation of genes associated with glycosaminoglycan binding, cell-matrix adhesion, and cell-substrate adhesion. Computational findings were substantiated by experimental validation of expression of key genes involved in two critical pathways affected by decitabine (TGF-β and Hh). Gene-expression profiling identified specific pathways altered by decitabine and associated with platinum-resensitization and clinical benefit in OC. Our data could influence patient stratification for future studies using epigenetic therapies.

KW - Chemosensitization

KW - Decitabine

KW - DNA methylation

KW - Gene expression

KW - Pathway analysis

KW - Platinum resistant ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84903532856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903532856&partnerID=8YFLogxK

M3 - Article

C2 - 25003579

AN - SCOPUS:84903532856

VL - 5

SP - 3579

EP - 3589

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -